DiaMedica Therapeutics, Inc. (DMAC) has been on a downward spiral lately with significant selling pressure. After declining 19.8% over the past four weeks, the stock looks well positioned for a trend ...
DiaMedica Therapeutics, Inc. (DMAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DMAC's 50-day simple moving average ...
Detailed price information for Diamedica Therapeutics Inc (DMAC-Q) from The Globe and Mail including charting and trades.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DiaMedica Therapeutics, Inc. (DMAC) is a stock that can certainly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results